▶ 調査レポート

世界の急性呼吸窮迫症候群(ARDS)治療市場2022-2028:経口、静脈内注射、筋肉内注射

• 英文タイトル:Acute Respiratory Distress Syndrome (ARDS) Treatment Market, Global Outlook and Forecast 2022-2028

Market Monitor Globalが調査・発行した産業分析レポートです。世界の急性呼吸窮迫症候群(ARDS)治療市場2022-2028:経口、静脈内注射、筋肉内注射 / Acute Respiratory Distress Syndrome (ARDS) Treatment Market, Global Outlook and Forecast 2022-2028 / MR2211MG10657資料のイメージです。• レポートコード:MR2211MG10657
• 出版社/出版日:Market Monitor Global / 2022年11月
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(納期:2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥481,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥625,300 (USD4,225)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査資料は次の情報を含め、急性呼吸窮迫症候群(ARDS)治療のグローバル市場規模と予測を記載しています。・急性呼吸窮迫症候群(ARDS)治療のグローバル市場:売上、2017年-2022年、2023年-2028年
・急性呼吸窮迫症候群(ARDS)治療のグローバル市場:販売量、2017年-2022年、2023年-2028年
・世界のトップ5企業、2021年

急性呼吸窮迫症候群(ARDS)治療のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000%のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「経口」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。

急性呼吸窮迫症候群(ARDS)治療のグローバル主要企業は、Gilead Sciences Inc.、 Terumo Corporation、 Getinge Ab、 Livanova Plc、 Medtronic、 Alung Technologies, Inc.、 Armstrong Medical、 Besmed Health Business Corp.、 Dragerwerk Ag & Co. Kgaa、 Eurosets、 F. Hoffmann-la Roche Ltd.、 Fisher & Paykel Healthcare Limited、 Fresenius Se & Co. Kgaa、 Hamilton Medical、 Nice Neotech Medical Systems Pvt.ltd.、 Nipなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル(MMG)社は、急性呼吸窮迫症候群(ARDS)治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の急性呼吸窮迫症候群(ARDS)治療市場:タイプ別、2017年-2022年、2023年-2028年
世界の急性呼吸窮迫症候群(ARDS)治療市場:タイプ別市場シェア、2021年
・経口、静脈内注射、筋肉内注射

世界の急性呼吸窮迫症候群(ARDS)治療市場:用途別、2017年-2022年、2023年-2028年
世界の急性呼吸窮迫症候群(ARDS)治療市場:用途別市場シェア、2021年
・病院薬局、小売薬局、オンライン薬局

世界の急性呼吸窮迫症候群(ARDS)治療市場:地域・国別、2017年-2022年、2023年-2028年
世界の急性呼吸窮迫症候群(ARDS)治療市場:地域別市場シェア、2021年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における急性呼吸窮迫症候群(ARDS)治療のグローバル売上、2017年-2022年
・主要企業における急性呼吸窮迫症候群(ARDS)治療のグローバル売上シェア、2021年
・主要企業における急性呼吸窮迫症候群(ARDS)治療のグローバル販売量、2017年-2022年
・主要企業における急性呼吸窮迫症候群(ARDS)治療のグローバル販売量シェア、2021年

さらに、当レポートは主要企業のプロファイルを提示します。
Gilead Sciences Inc.、 Terumo Corporation、 Getinge Ab、 Livanova Plc、 Medtronic、 Alung Technologies, Inc.、 Armstrong Medical、 Besmed Health Business Corp.、 Dragerwerk Ag & Co. Kgaa、 Eurosets、 F. Hoffmann-la Roche Ltd.、 Fisher & Paykel Healthcare Limited、 Fresenius Se & Co. Kgaa、 Hamilton Medical、 Nice Neotech Medical Systems Pvt.ltd.、 Nip

*************************************************************

・調査・分析レポートの概要
急性呼吸窮迫症候群(ARDS)治療市場の定義
市場セグメント
世界の急性呼吸窮迫症候群(ARDS)治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の急性呼吸窮迫症候群(ARDS)治療市場規模
世界の急性呼吸窮迫症候群(ARDS)治療市場規模:2021年 VS 2028年
世界の急性呼吸窮迫症候群(ARDS)治療市場規模と予測 2017年-2028年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの急性呼吸窮迫症候群(ARDS)治療の売上
グローバルトップ3およびトップ5企業、2021年売上ベース
グローバル企業の急性呼吸窮迫症候群(ARDS)治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:経口、静脈内注射、筋肉内注射
急性呼吸窮迫症候群(ARDS)治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院薬局、小売薬局、オンライン薬局
急性呼吸窮迫症候群(ARDS)治療の用途別グローバル売上・予測

・地域別市場分析
地域別急性呼吸窮迫症候群(ARDS)治療市場規模 2021年と2028年
地域別急性呼吸窮迫症候群(ARDS)治療売上・予測
北米市場
- アメリカの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- カナダの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- メキシコの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
ヨーロッパ市場
- ドイツの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- フランスの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- イギリスの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- イタリアの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- ロシアの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
アジア市場
- 中国の急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- 日本の急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- 韓国の急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- 東南アジアの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- インドの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
南米市場
- ブラジルの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- アルゼンチンの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
中東・アフリカ市場
- トルコの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- イスラエルの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- サウジアラビアの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年
- UAEの急性呼吸窮迫症候群(ARDS)治療市場規模2017年-2028年

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Gilead Sciences Inc.、 Terumo Corporation、 Getinge Ab、 Livanova Plc、 Medtronic、 Alung Technologies, Inc.、 Armstrong Medical、 Besmed Health Business Corp.、 Dragerwerk Ag & Co. Kgaa、 Eurosets、 F. Hoffmann-la Roche Ltd.、 Fisher & Paykel Healthcare Limited、 Fresenius Se & Co. Kgaa、 Hamilton Medical、 Nice Neotech Medical Systems Pvt.ltd.、 Nip
...

This report contains market size and forecasts of Acute Respiratory Distress Syndrome (ARDS) Treatment in Global, including the following market information:
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Acute Respiratory Distress Syndrome (ARDS) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acute Respiratory Distress Syndrome (ARDS) Treatment include Gilead Sciences Inc., Terumo Corporation, Getinge Ab, Livanova Plc, Medtronic, Alung Technologies, Inc., Armstrong Medical, Besmed Health Business Corp. and Dragerwerk Ag & Co. Kgaa, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Respiratory Distress Syndrome (ARDS) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segment Percentages, by Type, 2021 (%)
Oral
Intravenous Injection
Intramuscular Injection
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Respiratory Distress Syndrome (ARDS) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Acute Respiratory Distress Syndrome (ARDS) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences Inc.
Terumo Corporation
Getinge Ab
Livanova Plc
Medtronic
Alung Technologies, Inc.
Armstrong Medical
Besmed Health Business Corp.
Dragerwerk Ag & Co. Kgaa
Eurosets
F. Hoffmann-la Roche Ltd.
Fisher & Paykel Healthcare Limited
Fresenius Se & Co. Kgaa
Hamilton Medical
Nice Neotech Medical Systems Pvt.ltd.
Nipro
Pfizer Inc.
Resmed
Smiths Medical
Weinmann Emergency Medical Technology Gmbh+co. Kg

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Overall Market Size
2.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size: 2021 VS 2028
2.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Acute Respiratory Distress Syndrome (ARDS) Treatment Players in Global Market
3.2 Top Global Acute Respiratory Distress Syndrome (ARDS) Treatment Companies Ranked by Revenue
3.3 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Acute Respiratory Distress Syndrome (ARDS) Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Acute Respiratory Distress Syndrome (ARDS) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Acute Respiratory Distress Syndrome (ARDS) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Acute Respiratory Distress Syndrome (ARDS) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Acute Respiratory Distress Syndrome (ARDS) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Markets, 2021 & 2028
4.1.2 Oral
4.1.3 Intravenous Injection
4.1.4 Intramuscular Injection
4.2 By Type – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue & Forecasts
4.2.1 By Type – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2022
4.2.2 By Type – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2023-2028
4.2.3 By Type – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.2 By Application – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue & Forecasts
5.2.1 By Application – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2022
5.2.2 By Application – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2023-2028
5.2.3 By Application – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2021 & 2028
6.2 By Region – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue & Forecasts
6.2.1 By Region – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2022
6.2.2 By Region – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2023-2028
6.2.3 By Region – Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country – North America Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2028
6.3.2 US Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.3.3 Canada Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.3.4 Mexico Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country – Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2028
6.4.2 Germany Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.3 France Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.4 U.K. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.5 Italy Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.6 Russia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.4.8 Benelux Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region – Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2028
6.5.2 China Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.5.3 Japan Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.5.4 South Korea Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.5.6 India Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country – South America Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2028
6.6.2 Brazil Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.6.3 Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, 2017-2028
6.7.2 Turkey Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.7.3 Israel Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
6.7.5 UAE Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Gilead Sciences Inc.
7.1.1 Gilead Sciences Inc. Corporate Summary
7.1.2 Gilead Sciences Inc. Business Overview
7.1.3 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.1.4 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.1.5 Gilead Sciences Inc. Key News
7.2 Terumo Corporation
7.2.1 Terumo Corporation Corporate Summary
7.2.2 Terumo Corporation Business Overview
7.2.3 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.2.4 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.2.5 Terumo Corporation Key News
7.3 Getinge Ab
7.3.1 Getinge Ab Corporate Summary
7.3.2 Getinge Ab Business Overview
7.3.3 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.3.4 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.3.5 Getinge Ab Key News
7.4 Livanova Plc
7.4.1 Livanova Plc Corporate Summary
7.4.2 Livanova Plc Business Overview
7.4.3 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.4.4 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.4.5 Livanova Plc Key News
7.5 Medtronic
7.5.1 Medtronic Corporate Summary
7.5.2 Medtronic Business Overview
7.5.3 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.5.4 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.5.5 Medtronic Key News
7.6 Alung Technologies, Inc.
7.6.1 Alung Technologies, Inc. Corporate Summary
7.6.2 Alung Technologies, Inc. Business Overview
7.6.3 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.6.4 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.6.5 Alung Technologies, Inc. Key News
7.7 Armstrong Medical
7.7.1 Armstrong Medical Corporate Summary
7.7.2 Armstrong Medical Business Overview
7.7.3 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.7.4 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.7.5 Armstrong Medical Key News
7.8 Besmed Health Business Corp.
7.8.1 Besmed Health Business Corp. Corporate Summary
7.8.2 Besmed Health Business Corp. Business Overview
7.8.3 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.8.4 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.8.5 Besmed Health Business Corp. Key News
7.9 Dragerwerk Ag & Co. Kgaa
7.9.1 Dragerwerk Ag & Co. Kgaa Corporate Summary
7.9.2 Dragerwerk Ag & Co. Kgaa Business Overview
7.9.3 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.9.4 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.9.5 Dragerwerk Ag & Co. Kgaa Key News
7.10 Eurosets
7.10.1 Eurosets Corporate Summary
7.10.2 Eurosets Business Overview
7.10.3 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.10.4 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.10.5 Eurosets Key News
7.11 F. Hoffmann-la Roche Ltd.
7.11.1 F. Hoffmann-la Roche Ltd. Corporate Summary
7.11.2 F. Hoffmann-la Roche Ltd. Business Overview
7.11.3 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.11.4 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.11.5 F. Hoffmann-la Roche Ltd. Key News
7.12 Fisher & Paykel Healthcare Limited
7.12.1 Fisher & Paykel Healthcare Limited Corporate Summary
7.12.2 Fisher & Paykel Healthcare Limited Business Overview
7.12.3 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.12.4 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.12.5 Fisher & Paykel Healthcare Limited Key News
7.13 Fresenius Se & Co. Kgaa
7.13.1 Fresenius Se & Co. Kgaa Corporate Summary
7.13.2 Fresenius Se & Co. Kgaa Business Overview
7.13.3 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.13.4 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.13.5 Fresenius Se & Co. Kgaa Key News
7.14 Hamilton Medical
7.14.1 Hamilton Medical Corporate Summary
7.14.2 Hamilton Medical Business Overview
7.14.3 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.14.4 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.14.5 Hamilton Medical Key News
7.15 Nice Neotech Medical Systems Pvt.ltd.
7.15.1 Nice Neotech Medical Systems Pvt.ltd. Corporate Summary
7.15.2 Nice Neotech Medical Systems Pvt.ltd. Business Overview
7.15.3 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.15.4 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.15.5 Nice Neotech Medical Systems Pvt.ltd. Key News
7.16 Nipro
7.16.1 Nipro Corporate Summary
7.16.2 Nipro Business Overview
7.16.3 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.16.4 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.16.5 Nipro Key News
7.17 Pfizer Inc.
7.17.1 Pfizer Inc. Corporate Summary
7.17.2 Pfizer Inc. Business Overview
7.17.3 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.17.4 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.17.5 Pfizer Inc. Key News
7.18 Resmed
7.18.1 Resmed Corporate Summary
7.18.2 Resmed Business Overview
7.18.3 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.18.4 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.18.5 Resmed Key News
7.19 Smiths Medical
7.19.1 Smiths Medical Corporate Summary
7.19.2 Smiths Medical Business Overview
7.19.3 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.19.4 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.19.5 Smiths Medical Key News
7.20 Weinmann Emergency Medical Technology Gmbh+co. Kg
7.20.1 Weinmann Emergency Medical Technology Gmbh+co. Kg Corporate Summary
7.20.2 Weinmann Emergency Medical Technology Gmbh+co. Kg Business Overview
7.20.3 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Major Product Offerings
7.20.4 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue in Global Market (2017-2022)
7.20.5 Weinmann Emergency Medical Technology Gmbh+co. Kg Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer